Leading European health centers to improve cranial radiosurgery with Elekta’s new Leksell Gamma Knife Icon

STOCKHOLM, July 13 – Three foremost medical centers in the United Kingdom and
Germany have ordered and are now planning upgrades to Elekta’s latest generation
stereotactic radiosurgery system for the brain, Leksell Gamma Knife®
Icon™ (http://www.careforthebrain.com/), to provide the most advanced brain
radiosurgery treatments for their patients. The centers are University Medical
Centre Mannheim (UMC, Mannheim, Germany), Bristol Gamma Knife Centre, University
Hospitals Bristol NHS Foundation Trust (Bristol, UK) and The Leeds Gamma Knife
Centre at St James’s Institute of Oncology (Leeds, UK).
Leksell Gamma Knife Icon integrates advanced motion management, dose delivery
and imaging technologies, enabling clinicians to treat a wider variety of tumor
types and sizes. The system provides caregivers increased flexibility in how
radiosurgery is delivered, by allowing doctors to choose either frame-based or
frameless methods to immobilize the patient’s head, in addition to the option to
perform the treatment in a single session or multiple sessions. Icon also
permits physicians to choose the degree of precision needed for each patient
case – ranging from traditional high radiosurgery accuracy to ultra-precise
microradiosurgery.

The ability to deliver multi-fraction Gamma Knife radiosurgery to spare organs
-at-risk was important to clinicians at University Medical Centre Mannheim,
according to Frederik Wenz, MD, Professor and Chairman, Department of Radiation
Oncology at UMC.

“The steep dose gradients and mechanical stability offered by Gamma Knife Icon
allow sparing of normal tissue adjacent to the target,” he says. “In clinical
situations with sensitive structures within the target volume, sparing of organs
-at-risk can only be achieved by fractionation [i.e., multiple sessions]. By
fractionating the dose, we can use Icon in many clinical scenarios in which the
tumor is infiltrating normal tissue.”

Prof. Wenz anticipates treating the first patients with Gamma Knife Icon in late
August.

Dr. Alison Cameron, Clinical Lead for the Bristol Gamma Knife, says: “Icon will
allow Bristol to offer an intracranial stereotactic service without any
compromises. The system has the flexibility to ensure that the patient receives
the level of radiosurgery that they require clinically, whilst optimizing their
experience through flexibility in immobilization, scheduling and treatment. This
will lead to increased efficiency with improved quality, a truly
transformational service development.”

The team in Bristol expect to treat the first patient in September.

At The Leeds Gamma Knife Centre, Paul Hatfield, MD, Consultant Clinical
Oncologist, observes that the frameless immobilization and accurate
intrafraction monitoring of patient position are particularly valuable features
of Icon.

“These features will enable fractionated treatment for targets that would
normally be too large to treat, or where dose reductions would typically be
required, for safety reasons, that could potentially compromise treatment
effect,” Dr. Hatfield says. “The cone beam CT also will allow confirmation of
setup, which is an important part of modern radiotherapy. All of these benefits
combined will undoubtedly enhance the patient experience.”

“The Leeds Gamma Knife Centre, as part of Nova Healthcare, has always been
integrated within our busy radiotherapy and neuroscience department,” adds Nick
Phillips, MD, Consultant Neurosurgeon. “We operate as a close collaboration
between oncology, neurosurgery, medical physics and radiographers. Our
department is a leader in many stereotactic radiotherapy techniques and we are
keen to push forward this technology in the United Kingdom.”

The Gamma Knife Icon system is expected to be operational at The Leeds Gamma
Knife Centre by the end of 2015.

For more information on Leksell Gamma Knife Icon, visit www.careforthebrain.com.

Leksell Gamma Knife Icon is pending FDA 510(k) clearance.

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time

Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, e-mail: johan.andersson@elekta.com
Time zone: CET: Central European Time
The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 07:30 CET on July 13, 2015.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,800 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on NASDAQ Stockholm. Website: www.elekta.com.